Tweet
Supported by a federal contract, Saint Louis University will study a concept for a universal flu vaccine that is designed to protect people from influenza pandemics that could turn deadly as well as seasonal flu caused by the influenza A virus.
The National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health, selected SLU to work on the flu vaccine project, which has a total funding of $1.1 million.
"The ultimate aim of a universal influenza vaccine is to provide protection against all strains of influenza A viruses for many years without the need for annual vaccine strain changes or annual vaccinations," said Daniel Hoft, M.D., Ph.D., principal investigator of SLU's Vaccine and Treatment Evaluation Unit (VTEU) and director of the division of infectious diseases at Saint Louis University.
...
The National Institute of Allergy and Infectious Diseases (NIAID), which is part of the National Institutes of Health, selected SLU to work on the flu vaccine project, which has a total funding of $1.1 million.
"The ultimate aim of a universal influenza vaccine is to provide protection against all strains of influenza A viruses for many years without the need for annual vaccine strain changes or annual vaccinations," said Daniel Hoft, M.D., Ph.D., principal investigator of SLU's Vaccine and Treatment Evaluation Unit (VTEU) and director of the division of infectious diseases at Saint Louis University.
...
Comment